

Jennifer L Dodge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1823583/publications.pdf>

Version: 2024-02-01

62
papers

3,097
citations

185998

28
h-index

161609

54
g-index

62
all docs

62
docs citations

62
times ranked

3148
citing authors

#	ARTICLE	IF	CITATIONS
1	Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria. <i>Hepatology</i> , 2015, 61, 1968-1977.	3.6	372
2	Development of a novel frailty index to predict mortality in patients with end-stage liver disease. <i>Hepatology</i> , 2017, 66, 564-574.	3.6	340
3	Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. <i>JAMA Oncology</i> , 2017, 3, 493.	3.4	242
4	Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrALIT) study. <i>Hepatology</i> , 2016, 63, 574-580.	3.6	164
5	Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study. <i>Gastroenterology</i> , 2019, 156, 1675-1682.	0.6	151
6	National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. <i>JAMA Internal Medicine</i> , 2019, 179, 340.	2.6	150
7	Physical frailty after liver transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1986-1994.	2.6	113
8	Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 955-964.	2.4	101
9	National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. <i>Hepatology</i> , 2020, 71, 943-954.	3.6	101
10	Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. <i>Hepatology</i> , 2018, 68, 449-461.	3.6	84
11	Changes in frailty are associated with waitlist mortality in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 575-581.	1.8	82
12	Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. <i>Journal of Hepatology</i> , 2020, 73, 516-522.	1.8	78
13	Alpha-Fetoprotein Decrease from $> 1,000$ to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. <i>Hepatology</i> , 2019, 69, 1193-1205.	3.6	72
14	Split Liver Transplantation and Pediatric Waitlist Mortality in the United States: Potential for Improvement. <i>Transplantation</i> , 2019, 103, 552-557.	0.5	68
15	Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. <i>American Journal of Transplantation</i> , 2018, 18, 1206-1213.	2.6	67
16	Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease. <i>Liver Transplantation</i> , 2015, 21, 1286-1294.	1.3	65
17	Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. <i>Gastroenterology</i> , 2021, 161, 1502-1512.	0.6	57
18	Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. <i>Liver Transplantation</i> , 2016, 22, 178-187.	1.3	51

#	ARTICLE	IF	CITATIONS
19	Are There Upper Limits in Tumor Burden for Downstaging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the AllComers Protocol. <i>Hepatology</i> , 2019, 70, 1185-1196.	3.6	48
20	Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates. <i>Hepatology</i> , 2021, 73, 1132-1139.	3.6	48
21	Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1786-1791.e1.	2.4	47
22	Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the AVENA Criteria. <i>Liver Transplantation</i> , 2019, 25, 207-216.	1.3	42
23	Outcomes for liver transplant candidates listed with low model for end-stage liver disease score. <i>Liver Transplantation</i> , 2015, 21, 1403-1409.	1.3	40
24	Increasing Liver Transplantation Waitlist Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. <i>Liver Transplantation</i> , 2018, 24, 1346-1356.	1.3	39
25	Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCVviremic Donors. <i>Hepatology</i> , 2021, 73, 2110-2123.	3.6	37
26	Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation</i> , 2018, 102, 816-822.	0.5	36
27	Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. <i>Liver International</i> , 2018, 38, 553-563.	1.9	36
28	Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. <i>American Journal of Transplantation</i> , 2019, 19, 2210-2218.	2.6	32
29	History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist. <i>Transplantation</i> , 2018, 102, 794-802.	0.5	29
30	Multiple Listings as a Reflection of Geographic Disparity in Liver Transplantation. <i>Journal of the American College of Surgeons</i> , 2014, 219, 496-504.	0.2	27
31	A novel waitlist dropout score for hepatocellular carcinoma – identifying a threshold that predicts worse post-transplant survival. <i>Journal of Hepatology</i> , 2021, 74, 829-837.	1.8	25
32	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. <i>Transplantation</i> , 2020, 104, 2078-2086.	0.5	24
33	Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. <i>JAMA Network Open</i> , 2019, 2, e1910326.	2.8	23
34	Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2790-2799.e4.	2.4	21
35	Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. <i>American Journal of Transplantation</i> , 2021, 21, 3148-3156.	2.6	18
36	Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. <i>Liver Transplantation</i> , 2020, 26, 1100-1111.	1.3	17

#	ARTICLE	IF	CITATIONS
37	Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease. <i>Hepatology</i> , 2020, 72, 130-139.	3.6	16
38	Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. <i>Liver Transplantation</i> , 2020, 26, 662-672.	1.3	14
39	Changes and mediators of survival disparity among Black liver transplant recipients in the United States. <i>American Journal of Transplantation</i> , 2021, 21, 3883-3893.	2.6	11
40	Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics. <i>Liver Transplantation</i> , 2015, 21, 1365-1373.	1.3	10
41	Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list. <i>Hepatology</i> , 2017, 66, 1144-1150.	3.6	10
42	The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2022, 28, 376-385.	1.3	10
43	The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury—The Women's Interagency HIV Study. <i>PLoS ONE</i> , 2017, 12, e0181004.	1.1	9
44	Excess Mortality After Liver Transplantation in Young Women With Alcohol-Associated Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 551-559.	0.2	9
45	National experience with living donor liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2022, 28, 1144-1157.	1.3	8
46	Pregnancies With Cirrhosis Are Rising and Associated With Adverse Maternal and Perinatal Outcomes. <i>American Journal of Gastroenterology</i> , 2022, 117, 445-452.	0.2	8
47	The corrected donor age for hepatitis C virus-infected liver transplant recipients. <i>Liver Transplantation</i> , 2015, 21, 1022-1030.	1.3	7
48	Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. <i>Clinical Transplantation</i> , 2016, 30, 1140-1145.	0.8	6
49	Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1180-1185.e2.	2.4	6
50	Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. <i>Clinical Transplantation</i> , 2017, 31, e13107.	0.8	5
51	Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization. <i>Transplantation</i> , 2021, 105, 824-831.	0.5	5
52	Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation. <i>Clinical Transplantation</i> , 2022, 36, e14527.	0.8	5
53	Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2020, 104, 988-995.	0.5	3
54	Response to clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation. <i>Liver International</i> , 2016, 36, 611-611.	1.9	2

#	ARTICLE	IF	CITATIONS
55	Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort. <i>Hpb</i> , 2021, , .	0.1	2
56	Impact of body mass index on posttransplant outcomes reexamined. <i>Liver Transplantation</i> , 2016, 22, 261-262.	1.3	1
57	REPLY:. <i>Hepatology</i> , 2019, 70, 1491-1492.	3.6	1
58	No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2021, 27, 1680-1681.	1.3	1
59	Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. <i>Transplant International</i> , 2022, 35, 10182.	0.8	1
60	Reply. <i>Hepatology</i> , 2018, 67, 2059-2060.	3.6	0
61	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 574-575.	2.4	0
62	Transplantation, HIV Serostatus and Registry Data, Room for Improvement. <i>American Journal of Transplantation</i> , 2022, , .	2.6	0